ADVFN - Advanced Financial Network.
HOME» NASDAQ » I » ISIS Stock Price » ISIS Stock News

Isis Pharmaceuticals Share News

 Isis Pharmaceuticals (mm) Stock Price
ISIS Stock Price
 Isis Pharmaceuticals (mm) Stock Chart
ISIS Stock Chart
 Isis Pharmaceuticals (mm) Stock News
ISIS Stock News
 Isis Pharmaceuticals (mm) Company Information
ISIS Company Information
 Isis Pharmaceuticals (mm) Stock Trades
ISIS Stock Trades

Sanofi: Strategic Partnership With Regulus Therapeutics

PARIS -(Dow Jones)- French pharmaceutical group Sanofi Aventis (SNY) and U.S.-basec company Regulus Inc. Tuesday said they entered into a global strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance will initially focus on the therapeutic area of fibrosis. MAIN FACTS: - MicroRNAs (micro-RiboNucleic Acid) are a new class of small non-coding RNAs that regulate gene expression by interfering with translation or stability of target messenger RNA transcripts. Endogenous microRNAs regulate the expression of over one-third of all human genes. The association of microRNA dysfunction with disease phenotypes has given rise to an entirely new class of pharmaceutically relevant targets. - Sanofi-Aventis and Regulus will collaborate on microRNA drug discovery and preclinical development for up to four microRNA targets, including the lead fibrosis program targeting microRNA-21. Sanofi-Aventis also received an option, which if exercised, provides access to the technology to develop and commercialize other micro-RNA based therapeutics, beyond the first four targets. - Regulus will receive a $25 million upfront fee and a future $10 million equity investment subject to mutual agreement on company valuation. The alliance could be valued at over $750 million when taking into account upfront payments, equity investment, research funding, and potential near-term preclinical, clinical and commercial milestone payments for multiple products. - Regulus was formed in 2007 and is jointly owned by Alnylam Pharmaceuticals and Isis Pharmaceuticals. - By Paris Bureau, Dow Jones Newswires; +331-4017-1740;

Stock News for Isis Pharmaceuticals (ISIS)
11/15/201308:53:19D. E. Shaw & Co. LP 3Q 13F: Largest Eliminations
11/15/201308:53:15D. E. Shaw & Co. LP 3Q 13F: Largest Purchases
11/15/201308:53:15D. E. Shaw & Co. LP 3Q 13F: Largest Sales
11/15/201308:53:15D. E. Shaw & Co. LP 3Q 13F: Largest Eliminations -2-
09/09/201308:01:24Biogen, Isis Agree to Collaborate on Neurological Treatments
06/03/201308:11:11Isis Earns $10 Million Milestone Payment from AstraZeneca Cancer-Drug...
04/08/201309:59:37Isis Pharmaceuticals, Roche to Collaborate on Huntington's Disease...
01/29/201319:10:12FDA Approves Sanofi's Kynamro to Treat Rare Cholesterol Disorder
12/14/201208:32:34Sanofi's Genzyme: EU Regulator Issues Negative Opinion for Kynamro
12/14/201208:28:19Isis, Genzyme: CHMP Issues Negative Opinion on Cholesterol Drug
12/13/201209:24:27Isis's Transthyretin Amyloidosis Treatment Gets Fast-Track FDA...
12/11/201207:52:51Isis Strikes Cancer Targets Agreement Worth $31 Million With...
10/18/201215:56:36FDA Panel Supports Genzyme, Isis Drug Mipomersen on 9-6 Vote
06/29/201209:18:18Biogen Idec, Isis Pharma In Pact for Drug to Treat Steinart Disease
01/04/201209:39:20Biogen, Isis Enter Collaboration On Spinal Atrophy Treatment
11/10/201110:21:31Sanofi, Regeneron's Anti-Cholesterol Drug Has Good Test Results
02/16/201115:01:13Sanofi Deal Brings Risk, Opportunity To Genzyme Partners
01/12/201111:16:47Isis CEO Sees Partner Genzyme Being Acquired By Sanofi -Reuters
08/04/201013:26:34Isis, Genzyme Cholesterol Drug Works, But Safety Concerns Loom

Isis Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations